# RBC Capital

Type: Company (RY)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/rbc-capital
Canonical HTML page: https://getbiobrief.com/entity/rbc-capital

## Timeline

- **2026-06-12**: SEC filings and market close — Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.
- **2026-06-11**: Insider sales executed — Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.
- **2026-05-05**: Q1 2026 earnings — uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.
- **2026-03-09**: RBC upgrade — RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.

## Recent coverage (4 stories)

### 3 uniQure Directors Each Sell 1,993 Shares; Stock Now $27.57
2026-08-05 19:24:48 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn.
Full story: https://getbiobrief.com/story/uniqure-insider-sales-3-directors-sell-1993-shares-27-57

### Abbott Beats Q2 with $12.59B Revenue, Analysts Raise PT to $134; UNH Also Surges
2026-07-25 20:28:16 · Sentiment: Bullish · Impact: 7/10 · Sources: 1

Abbott Laboratories reported Q2 revenue of $12.59 billion (+13% YoY), beating estimates and raising its full-year EPS guidance. Analysts hiked price targets in response, with BTIG going to $134, reflecting confidence in its diversified healthcare portfolio and pipeline. UnitedHealth also delivered a massive EPS beat, but Abbott’s medtech and diagnostics momentum carries particular relevance for the biopharma sector.
Full story: https://getbiobrief.com/story/abbott-unh-q2-2026-beat-analyst-target-hikes-bio

### RBC Capital Backs Eli Lilly’s Retatrutide as Next-Gen Obesity Powerhouse
2026-03-20 05:29:24 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

RBC Capital has reaffirmed its bullish outlook on Eli Lilly’s Retatrutide, identifying the triple-agonist as a primary long-term growth driver despite mixed clinical trial data. Analysts suggest that the drug's unprecedented weight-loss efficacy will likely overshadow manageable safety concerns, securing Lilly's dominance in the metabolic health sector.
Full story: https://getbiobrief.com/story/eli-lilly-retatrutide-rbc-capital-growth-driver

### RBC Capital Initiates AbbVie Coverage with Outperform Rating
2026-02-27 14:46:31 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.
Full story: https://getbiobrief.com/story/rbc-capital-abbvie-outperform-rating-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.